CTOs on the Move

Senti Bio

www.sentibio.com

 
Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.sentibio.com
  • 2 Corporate Drive First Floor
    South San Francisco, CA USA 94080
  • Phone: 510.520.8691

Executives

Name Title Contact Details
Philip Lee
 Co-Founder and Chief Technology Officer Profile

Funding

Senti Bio raised $53M on 02/27/2018

Similar Companies

BioMarker Strategies

BioMarker Strategies is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Provident Clinical Research and Consulting

Provident Clinical Research and Consulting is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synchem

Synchem, Inc. is a Elk Grove Village, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ReCode Therapeutics

ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases with significant unmet medical need.

RuiYi

RuiYi is focused on the discovery and development of novel biologic therapeutics that have the potential to be disruptive globally. In addition to RYI-018 and RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company's technologies, including the iCAPS (intramembranous Conformation Antigen Presenting System). Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators. RuiYi's executive management team has offices in La Jolla, California, and RuiYi's discovery efforts and research facility are located in in the Zhangjiang Hi-Tech Park in Pudong, Shanghai, China.